This clinical trial will use product CHI-902. The trial will happen over four weeks. Its first phase will involve participants taking 150 mg of CBD oil for the first week. The CBD oil will be divided into 50 mg and given three times per day. After the first week, the dosage will increase to 300 mg per day. This new dosage will be for three weeks.
Evaluation of the trial
This clinical study aims at evaluating the efficiency, tolerability, therapeutic effects, and safety of CBD oil. The study will also evaluate the effects of CHI-902 on the human endocannabinoids anandamide (the “bliss molecule”) and 2-AG, which are naturally occurring in the human body. The study will assess how CHI-902 affects two elements before and after the procedure.
This trial will assess and examine the following and compare with the placebo results:
- The efficiency of CHI-902 with social anxiety disorder.
- The tolerability and safety of CHI-902 in participants with social anxiety disorder.
- The effects of CHI-902 on various biomarkers in cases of social anxiety disorder.